Rhodococcus bacteria as a source of novel antibiotics

红球菌作为新型抗生素的来源

• 批准号: 1898611
• 金额: --
• 依托单位: University of Warwick
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-1898611
• 关键词: Rhodococcus; bacteria; source; novel; antibiotics

In the last 25 years the discovery rate of new antibiotics has plummeted. In the same time period, this problem has been compounded by the rapid rise of drug resistant bacteria for many of the antibiotics that are currently known. At the moment, the majority of the antibiotics that are used to treat bacterial infections in medicine, agriculture and veterinarian treatment originate from the bacterial genus Streptomyces. It is hoped that other actinomycetes genera such as Rhodococcus have the same capability as the Streptomyces. The idea of this project is to look at Rhodococcus bacteria as a source for novel antibiotics due to them also being actinomycetes and having analogous genetic potential to Streptomyces that may indicate the presence of antimicrobial compound production. The regulatory system in Streptomyces has recently been characterised and it is believed that there is an analogue of this found in the Rhodococcus genome. The aim of this study is to understand the regulation of the Rhodococcus pathways that will ultimately lead to the development

在过去的25年里，新抗生素的发现率急剧下降。在同一时期，这个问题由于目前已知的许多抗生素的耐药细菌的迅速增加而变得更加复杂。目前，大多数用于治疗医学，农业和兽医治疗中细菌感染的抗生素都来自细菌链霉菌属。希望其他放线菌属如红球菌属也具有与链霉菌相同的能力。该项目的想法是将红球菌细菌作为新型抗生素的来源，因为它们也是放线菌，并且具有与链霉菌类似的遗传潜力，这可能表明存在抗微生物化合物生产。链霉菌中的调节系统最近已被表征，并且据信在红球菌基因组中发现了类似物。本研究的目的是了解红球菌途径的调节，最终导致发展